The Effects of Single‐ and Multiple‐dose Administration of Bococizumab (RN316/PF‐04950615), a Humanized IgG2Δa Monoclonal Antibody Binding Proprotein Convertase Subtilisin/kexin Type 9, in Hypercholesterolemic Subjects Treated with and Without Atorvastatin: Results from Four Phase I Studies
Cardiovascular therapeutics（2017）
Key words
bococizumab,humanized monoclonal antibody,hypercholesterolemia,low-density lipoprotein cholesterol,phase I clinical trial,proprotein convertase subtilisin,kexin type 9 inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined